Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism
Crossref DOI link: https://doi.org/10.2337/db16-0049
Published Online: 2016-04-05
Published Print: 2016-07-01
Update policy: https://doi.org/10.2337/ada-journal-policies
Briand, François
Mayoux, Eric
Brousseau, Emmanuel
Burr, Noémie
Urbain, Isabelle
Costard, Clément
Mark, Michael
Sulpice, Thierry
Funding for this research was provided by:
Boehringer Ingelheim
Version of Record valid from 2017-01-01
